[1] SIEGEL RL, MILLER KD, JEMAL A, et al.Cancer Statistics, 2017[J].CA Cancer J Clin, 2017, 67(1):7. doi: 10.3322/caac.21387
[2] YAN X, YU Q, GUO L, et al.Positively charged combinatory drug delivery systems against multi-drug-resistant breast cancer:Beyond the drug combination[J].ACS Appl Mater Interfaces, 2017, 9(8):6804. doi: 10.1021/acsami.6b14244
[3] HUANG L, WEI Y, SHEN S, et al.Therapeutic effect of apatinib on overall survival is mediated by prolonged progression free survival in advanced gastric cancer patient[J].Oncotarget, 2017, 8(17):29346. doi: 10.18632/oncotarget.12897
[4] 张桂芳, 黄普超, 周林静, 等.阿帕替尼治疗多线以上治疗失败9例晚期乳腺癌的临床疗效[J].肿瘤学杂志, 2017, 23(9):827. doi: 10.3969/j.issn.1009-0460.2017.09.012
[5] HU T, LIU C, LI Q, et al.Apatinib+CPT-11+S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer:Case report and literature review[J].Medicine (Baltimore), 2018, 97(15):e0349. doi: 10.1097/MD.0000000000010349
[6] TIAN S, QUAN H, XIE C, et al.YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J].Cancer Sci, 2011, 102(7):1374. doi: 10.1111/j.1349-7006.2011.01939.x
[7] SCOTT AJ, MESSERSMITH WA, JIMENO A, et al.Apatinib:a promising oral anti-angiogenic agent in the treatment of multiple solid tumors[J].Drugs Today, 2015, 51(4):223. doi: 10.1358/dot.2015.51.4.2320599
[8] 安改丽, 李旭, 冯璐, 等.Apatinib联合5-Fu协同抑制乳腺癌MCF-7细胞的体外研究[J].实用癌症杂志, 2017, 32(5):702. doi: 10.3969/j.issn.1001-5930.2017.05.002
[9] 张圣村, 马敏, 徐丽丽.阿帕替尼逆转P-gp转运体介导的乳腺癌化疗多药耐药性的作用及其机制[J].肿瘤防治研究, 2018, 45(4):210. doi: 10.3971/j.issn.1000-8578.2018.17.1112
[10] 朱婉婷, 范雪梅, 位华, 等.基于网络药理学探讨阿帕替尼治疗乳腺癌的作用机制[J].中国药学杂志, 2016, 51(18):1569.
[11] HU X, ZHANG J, XU B, et al.Multicenter phase Ⅱ study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer[J].Int J Cancer, 2014, 135(8):1961. doi: 10.1002/ijc.28829
[12] HU X, CAO J, HU W, et al.Multicenter phase Ⅱ study of apatinib in non-triple-negative metastatic breast cancer[J].BMC Cancer, 2014, 14(6):820.
[13] 王晓蕊, 汪旭, 史业辉, 等.阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效观察[J].中国肿瘤临床, 2017, 44(15):769. doi: 10.3969/j.issn.1000-8179.2017.15.643
[14] 远丽芳, 刘俊宝, 秦岭, 等.阿帕替尼治疗多线治疗失败的转移性乳腺癌的疗效观察[J].癌症进展, 2017, 15(4):411.